STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement. BioArctic AB’s ...

BioArctic AB, a public Swedish biopharma company, recently announced that they received allowance of a patent application directed to a method of promoting axonal regeneration using a biodegradable ...

Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made.

Comments from the CEO, '2025 was a record year for BioArctic, with an operating profit of more than SEK 1.2 billion' 2025 was a fantastic year for BioArctic, with record financial results, another ...

BioArctic AB (publ), a Swedish research-based biopharma company, announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a ...

STOCKHOLM, April 21, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2025 has been published and is available on the company's website. The ...

STOCKHOLM, Feb. 18, 2022 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) continues to build the Nordic commercial organization ahead of a potential launch of the company's lead drug ...

The U.S. FDA’s three month extension of its review for Leqembi Iqlik has pushed a key regulatory decision further out, putting BioArctic (OM:BIOA B) back in focus for Alzheimer’s focused investors.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review ...

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi Iqlik was launched for weekly maintenance dosing and Eisai ...